Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Amylin Pharmaceuticals
So what: The once-weekly Bydureon injection, which Amylin is co-developing with Alkermes
Now what: Amylin remains far too speculative for most investors. While Bydureon could certainly still get approved, there now seems to be a lot of concern on Wall Street about how it could compete. Amylin has posted less-than-stellar sales over the past few years, and with Bydureon's prospects not shining as brightly as they once did, there's very little reason to get involved.
Interested in more info on Amylin? Add it to your watchlist.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.